Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

New Technique May Lead to Rejection-Free Adult Stem Cells

By BiotechDaily International staff writers
Posted on 14 Aug 2012
Patient-specific, blood-producing stem cells could soon be generated in the laboratory, eliminating the need for harvesting bone marrow--or finding a matching donor--for patients needing a bone marrow transplant. German scientists have generated blood-forming stem cells from pluripotent stem cells in the laboratory without using animal serum, a technique that could lead to the production of rejection-free adult stem cells.

Researchers Dr. Bernhard Schiedlmeier and Hannes Klump led the study, which was published August 6, 2012, in the journal STEM CELLS Translational Medicine.

The scientists used mouse embryonic stem cells to grow blood-forming stem cells in low-oxygen conditions in the lab without using any serum or supportive cells known as stroma. When they transplanted the blood-forming cells into mice, they found the cells were capable of rebuilding the mice’s blood-forming system.

This findings means that scientists may ultimately be able to create blood stem cells from transplant patients in a laboratory instead of than using stem cells from unrelated donors, avoiding hazardous graft versus host reactions. “If our protocol can be adapted to humans and combined with induced pluripotent stem cell technology, it will open the door to producing adult stem cells that a patient’s body should not reject,” Dr. Klump said.

“These researchers have made progress toward the idea of one day using a patient’s own skin cells, or other cell types, to make blood-producing cells in the laboratory,” said Anthony Atala, MD, editor of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine (Winston-Salem, NC, USA). “These findings are important for the translational aspects of using iPS cells.”

Dr. Schiedlmeier works in the department of experimental biology at Hannover Medical School (Germany) and Dr. Klump works at the Institute for Transfusion Medicine at University Hospital Essen (Germany).

Related Links:

Hannover Medical School
University Hospital Essen




Channels

Genomics/Proteomics

view channel
Image: The bone marrow of mice with normal ether lipid production (top) contains more white blood cells than are found in the bone marrow of mice with ether lipid deficiency (bottom) (Photo courtesy of Washington University School of Medicine).

Inactivating Fatty Acid Synthase Reduces Inflammation by Interfering with Neutrophil Membrane Function

The enzyme fatty acid synthase (FAS) was shown to regulate inflammation by sustaining neutrophil viability through modulation of membrane phospholipid composition. Neutrophils are the most abundant... Read more

Drug Discovery

view channel
Image: Researchers have attached two drugs—TRAIL and Dox—onto graphene strips. TRAIL is most effective when delivered to the external membrane of a cancer cell, while Dox is most effective when delivered to the nucleus, so the researchers designed the system to deliver the drugs sequentially, with each drug hitting a cancer cell where it will do the most damage (Photo courtesy of Dr. Zhen Gu, North Carolina State University).

Anticancer Drug Delivery System Utilizes Graphene Strip Transporters

The ongoing search by cancer researchers for targeted drug delivery systems has generated a novel approach that uses graphene strips to transport simultaneously the anticancer agents TRAIL (tumor necrosis... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Therapeutics

view channel
Image: Cancer cells infected with tumor-targeted oncolytic virus (red). Green indicates alpha-tubulin, a cell skeleton protein. Blue is DNA in the cancer cell nuclei (Photo courtesy of Dr. Rathi Gangeswaran, Bart’s Cancer Institute).

Innovative “Viro-Immunotherapy” Designed to Kill Breast Cancer Cells

A leading scientist has devised a new treatment that employs viruses to kill breast cancer cells. The research could lead to a promising “viro-immunotherapy” for patients with triple-negative breast cancer,... Read more

Business

view channel

Biotech Acquisition Designed to Accelerate the Development and Marketing of Immunosequencing Applications

Adaptive Biotechnologies Corp. (Seattle, WA, USA), a developer of next-generation sequencing (NGS) to profile T-cell and B-cell receptors, has acquired of Sequenta, Inc. (South San Francisco, CA, USA), which is expected to expedite and expand the use of innovative immunosequencing technology for researchers and clinicians... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.